Celldex Therapeutics (CLDX) CEO Marucci Buys 375,000 Shares

CEO Anthony Marucci Acquires 375,000 Shares

Celldex Therapeutics, Inc. (NasdaqCM: CLDX) saw its president and chief executive officer, Anthony Marucci, make a sizeable investment in the biotechnology firm. On June 25, 2026, the chief executive picked up 375,000 shares of stock. This transaction stands out due to its sheer scale, dwarfing typical individual trades and signaling strong internal belief from the top executive as the company develops treatments for inflammatory and allergic conditions.

Broad Leadership Buying Wave Across Celldex

The CEO's acquisition was not an isolated event but part of a coordinated cluster of purchases across the leadership team on June 25, 2026. Executive VP and CSO Tibor Keler acquired 115,000 shares, while SVP of Corporate Affairs and Administration Sarah Cavanaugh and SVP of Regulatory Affairs Margo Heath-Chiozzi each picked up 95,000 shares. Additionally, SVP and General Counsel Freddy Jimenez bought 93,000 shares, and directors Harry Penner Jr. and Herbert Conrad each acquired 26,000 shares on that same day.

Celldex Stock Trades in Mid-Range

Shares of Celldex traded around the $35.26 mark on the day of the publication. The biotechnology firm carries a market capitalization near $2.98 billion. The equity has moved between a 52-week low of $22.10 and a peak of $45.14 over the past year.

Wall Street Analyst Outlook

Research firms remain active following the company's clinical pipeline developments. On October 2, 2026, HC Wainwright & Co. reiterated its buy rating with a $64.00 price target. Earlier in September, Leerink Partners maintained an outperform rating while lifting its target to $88.00. Morgan Stanley kept an overweight rating with a $57.00 target on September 23, 2026, and Cantor Fitzgerald maintained an overweight rating with a $72.00 target on September 22, 2026. The broader analyst community maintains a consensus strong buy recommendation and a mean price target of $59.07 across 14 active opinions.

Biotechnology Pipeline Focus

Celldex Therapeutics works on developing therapeutic antibodies to treat severe inflammatory, allergic, and autoimmune diseases. Its clinical work centers on monoclonal and bispecific antibodies designed to target mast cell-driven conditions where current care falls short. Key programs include Barzolvolimab, which binds the KIT receptor to address chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis.

Upcoming Financial Milestones

Shareholders will look ahead to the company's next financial results report, which is currently scheduled for November 9, 2026. Market participants will track upcoming clinical updates and further filings to gauge operational progress following the recent insider activity.